At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 15 enrolled
Drug / intervention
Glycyrrhetic Acid +1 moredrug
Likely dose
Glycyrrhetic Acid 130 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Role of Mineralocorticoid Receptors in Vascular Function
In Brief
A Phase 3 clinical trial evaluating Glycyrrhetic Acid and Placebo for Apparent Mineralocorticoid Excess (AME). Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure under control.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsApparent Mineralocorticoid Excess (AME)
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2002
First PostedSep 2008
Primary CompletionSep 2009
TodayJul 2026
First PostedSep 25, 2008
Enrollment StartFeb 1, 2002
Primary CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 17.8 years ago
Interventions
Glycyrrhetic Aciddrug
130 mg daily for fourteen days
Placebodrug
Placebo daily for fourteen days